Methodology

An LC–MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent

*Author for correspondence:

E-mail Address: suzanne.parker@uq.edu.au

Burns, Trauma & Critical Care Research Centre, UQ Centre for Clinical Research, Brisbane, Australia

Search for more papers by this author

Yarmarly C Guerra Valero

Burns, Trauma & Critical Care Research Centre, UQ Centre for Clinical Research, Brisbane, Australia

Search for more papers by this author

Jenny L Ordóñez Mejia

Burns, Trauma & Critical Care Research Centre, UQ Centre for Clinical Research, Brisbane, Australia

Search for more papers by this author

Claire Roger

CHU Nimes, Serv Reanimat, Pole Anesthesie Reanimat Douleur Urgence, Nimes, France

Search for more papers by this author

Jeffrey Lipman

Burns, Trauma & Critical Care Research Centre, UQ Centre for Clinical Research, Brisbane, Australia

Department of Intensive Care Medicine, Royal Brisbane & Women's Hospital, Brisbane, Australia

Faculty of Health, Queensland University of Technology, Brisbane, Australia

Search for more papers by this author

Jason A Roberts

Burns, Trauma & Critical Care Research Centre, UQ Centre for Clinical Research, Brisbane, Australia

Faculty of Health, Queensland University of Technology, Brisbane, Australia

Department of Pharmacy, Royal Brisbane & Women's Hospital, Brisbane, Australia

Centre of Translational Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Australia

Search for more papers by this author

Steven C Wallis

Burns, Trauma & Critical Care Research Centre, UQ Centre for Clinical Research, Brisbane, Australia

Search for more papers by this author

Published Online:15 Jun 2017https://doi.org/10.4155/bio-2017-0019

View article

Abstract

Aim: Critical illness and medical interventions, such as renal replacement therapy, can cause changes to vancomycin pharmacokinetics and lead to suboptimal dosing. To comprehensively characterize vancomycin pharmacokinetic a method must measure vancomycin in a range of clinical matrices. Results: A LC–MS/MS method was developed using hydrophilic interaction liquid chromatography and microsample volumes, where possible. For all matrices, the linear concentration range was 1–100 μg/ml, interassay accuracy and precision was within 15%, and recovery above 80%. No matrix effects were observed. Calibration equivalence may be applied for some matrix combinations. Conclusion: A method for the analysis of vancomycin in plasma (total, unbound), urine and renal replacement therapy effluent, suitable for use in any patient pharmacokinetic study, has been developed and validated.

Keywords:

References

1 Tabah A, De Waele J, Lipman J et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J. Antimicrob. Chemother. 70(9), 2671–2677 (2015).
Medline CASGoogle Scholar
2 Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA. Glycopeptide antibiotics: back to the future. J. Antibiot. 67(9), 631–644 (2014).
Medline CASGoogle Scholar
3 Roberts JA, Choi GYS, Joynt GM et al. SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infect. Dis. 16, 8 (2016).
MedlineGoogle Scholar
4 Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 39(12), 2070–2082 (2013).
Medline CASGoogle Scholar
5 Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit. Care Med. 42(7), 1640–1650 (2014).
MedlineGoogle Scholar
6 Vila M, De Oliveira RM, Goncalves MM, Tubino M. Analytical methods for vancomycin determination in biological fluids and in pharmaceuticals. Quim. Nova 30(2), 395–399 (2007).
CASGoogle Scholar
7 Javorska L, Krcmova LK, Solichova D, Solich P, Kaska M. Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography – a review. J. Sep. Sci. 39(1), 6–20 (2016).
Medline CASGoogle Scholar
8 Hagihara M, Sutherland C, Nicolau DP. Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J. Chromatogr. Sci. 51(3), 201–207 (2013).
Medline CASGoogle Scholar
9 Li X, Wang F, Xu B et al. Determination of the free and total concentrations of vancomycin by two-dimensional liquid chromatography and its application in elderly patients. J. Chromatogr. B 969, 181–189 (2014).
Medline CASGoogle Scholar
10 Zhang JF, Yang XL, Zhang ZQ, Dong WC, Jiang Y. Accuracy of the analysis of free vancomycin concentration by ultrafiltration in various disease states. RSC Adv. 4(76), 40214–40222 (2014).
CASGoogle Scholar
11 Cao YR, Yu JC, Chen YC et al. Development and validation of a new ultra-performance liquid chromatographic method for vancomycin assay in serum and its application to therapeutic drug monitoring. Ther. Drug Monit. 36(2), 175–181 (2014).
Medline CASGoogle Scholar
12 Bijleveld Y, De Haan T, Toersche J et al. A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. J. Chromatogr. B 951, 110–118 (2014).
MedlineGoogle Scholar
13 Konig K, Kobold U, Fink G et al. Quantification of vancomycin in human serum by LC–MS/MS. Clin. Chem. Lab. Med. 51(9), 1761–1769 (2013).
MedlineGoogle Scholar
14 Oyaert M, Peersman N, Kieffer D et al. Novel LC–MS/MS method for plasma vancomycin: comparison with immunoassays and clinical impact. Clin. Chim. Acta 441, 63–70 (2015).
Medline CASGoogle Scholar
15 Sakamoto Y, Jinno Y, Shinodzuka I, Iwasaki Y, Ito R, Saito K. Sample cleanup using solid-phase dispersive extraction for determination of vancomycin in serum. Anal. Sci. 30(2), 271–275 (2014).
Medline CASGoogle Scholar
16 Tsai IL, Sun HY, Chen GY, Lin SW, Kuo CH. Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta 116, 593–603 (2013).
Medline CASGoogle Scholar
17 Berthoin K, Ampe E, Tulkens PM, Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int. J. Antimicrob. Agents 34(6), 555–560 (2009).
Medline CASGoogle Scholar
18 Jonsson O, Villar RP, Nilsson LB et al. Capillary microsampling of 25 μl blood for the determination of toxicokinetic parameters in regulatory studies in animals. Bioanalysis 4(6), 661–674 (2012).
CASGoogle Scholar
19 Parker SL, Dorofaeff T, Lipman J et al. Is there a role for microsampling in antibiotic pharmacokinetic studies? Expert Opin. Drug Metab. Toxicol. 12(6), 601–614 (2016).
Medline CASGoogle Scholar
20 Cheng C, Liu SR, Xiao DQ et al. LC-MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J. Chromatogr. B 878(28), 2831–2838 (2010).
Medline CASGoogle Scholar
21 Li L, Miles MV, Hall W, Carson SW. An improved micromethod for vancomycin determination by high-performance liquid-chromatography. Ther. Drug Monit. 17(4), 366–370 (1995).
Medline CASGoogle Scholar
22 Alsachim. Vancomycin-D12 TFA salt (2017). www.alsachim.com/product-C3831-glo.bal-Vancomycin-D12_TFA_salt.html.
Google Scholar
23 Royal Society of Chemistry. ChemSpider. (26 Jan 2017), CSID 14253 (2017).
Google Scholar
24 Twohig M. Quattro Micro Training Course. www.ecs.umass.edu/eve/facilities/equipment/Quattromicro/QMtrainingslidesch1.pdf.
Google Scholar
25 Page-Sharp M, Nunn T, Salman S et al. Validation and application of a dried blood spot ceftriaxone assay. Antimicrob. Agents Chemother. 60(1), 14–23 (2016).
Medline CASGoogle Scholar
26 Baietto L, D'avolio A, Ariaudo A et al. Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J. Chromatogr. B 936, 42–47 (2013).
Medline CASGoogle Scholar
27 Parker SL, Lipman J, Dimopoulos G, Roberts JA, Wallis SC. A validated method for the quantification of fosfomycin on dried plasma spots by HPLC–MS/MS: Application to a pilot pharmacokinetic study in humans. J. Pharm. Biomed. Anal. 115, 509–514 (2015).
Medline CASGoogle Scholar
28 Parker SL, Roberts JA, Lipman J, Wallis SC. Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. Bioanalysis 7(19), 2585–2595 (2015).
CASGoogle Scholar
29 Usman M, Hempel G. Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA). SpringerPlus 5, 7 (2016).
MedlineGoogle Scholar
30 Stove V, Coene L, Carlier M, De Waele JJ, Fiers T, Verstraete AG. Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance. Ther. Drug Monit. 37(2), 180–187 (2015).
Medline CASGoogle Scholar
31 Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. J. Clin. Pharmacol. 54(3), 318–323 (2014).
Medline CASGoogle Scholar

Vol. 9, No. 12

Metrics

Downloaded 434 times

History

Published online 15 June 2017

Published in print June 2017

Information

Keywords

Financial & competing interests disclosure

JA Roberts is a recipient of an Australian National Health and Medical Research Council Fellowship (APP1048652). The authors acknowledge funding from the Australian National Health and Medical Research Council for Project grants (APP1044941, APP1062040) and Centre of Research Excellence (APP1099452). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The clinical trial was performed in accordance with the principles laid down by the Australian guidelines for Good Clinical Practice and the applicable local regulatory requirements. The trial was approved by the Human Research & Ethics Committee Royal Brisbane and Women's Hospital for the project (HREC/13/QRBW/1). As this was a multicenter trial all other participating sites also obtained individual HREC approval.

PDF download